News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) Announces Approval Of Roche (RHHBY)’s Kadcyla® In The European Union


11/20/2013 9:34:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the European Commission has granted marketing approval for Kadcyla (trastuzumab emtansine; ado-trastuzumab emtansine in the US) in the European Union (EU). This event triggers a $5 million milestone payment to ImmunoGen.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES